Mutual of America Capital Management LLC Sells 473 Shares of Cencora, Inc. (NYSE:COR)

Mutual of America Capital Management LLC lowered its position in shares of Cencora, Inc. (NYSE:COR) by 2.2% in the fourth quarter, HoldingsChannel reports. The fund owned 21,055 shares of the company’s stock after selling 473 shares during the period. Mutual of America Capital Management LLC’s holdings in Cencora were worth $4,731,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Swedbank AB lifted its position in Cencora by 2.3% during the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock valued at $313,863,000 after purchasing an additional 31,104 shares during the period. Harbor Capital Advisors Inc. bought a new stake in shares of Cencora during the third quarter worth approximately $62,000. Intact Investment Management Inc. acquired a new position in Cencora in the third quarter valued at approximately $70,000. National Pension Service boosted its stake in Cencora by 16.8% in the third quarter. National Pension Service now owns 307,919 shares of the company’s stock valued at $69,306,000 after acquiring an additional 44,346 shares during the last quarter. Finally, QRG Capital Management Inc. grew its holdings in Cencora by 1.8% during the 3rd quarter. QRG Capital Management Inc. now owns 20,020 shares of the company’s stock worth $4,506,000 after acquiring an additional 351 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This represents a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 4,970 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the transaction, the chief executive officer now directly owns 51,070 shares of the company’s stock, valued at $13,022,850. This represents a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,648 shares of company stock valued at $2,862,342 over the last three months. Company insiders own 10.80% of the company’s stock.

Cencora Price Performance

NYSE COR opened at $253.35 on Wednesday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market cap of $49.13 billion, a price-to-earnings ratio of 36.04, a PEG ratio of 1.31 and a beta of 0.49. The business has a 50 day simple moving average of $242.78 and a 200 day simple moving average of $238.09. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $262.26.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.87%. Cencora’s dividend payout ratio (DPR) is 31.29%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on COR shares. StockNews.com downgraded Cencora from a “buy” rating to a “hold” rating in a research note on Tuesday. UBS Group increased their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Wells Fargo & Company raised their target price on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 29th. Evercore ISI upped their price target on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.